• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.

作者信息

da Silva Filipe Ana, Sreenu Vattipally, Hughes Joseph, Aranday-Cortes Elihu, Irving William L, Foster Graham R, Agarwal Kosh, Rosenberg William, Macdonald Douglas, Richardson Paul, Aldersley Mark A, Wiselka Martin, Ustianowski Andrew, McLauchlan John, Thomson Emma C

机构信息

MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.

Gastrointestinal and Liver Disorders Theme, NIHR Nottingham Biomedical Research Centre at the Nottingham University Hospitals NHS Trust and the University of Nottingham, UK.

出版信息

J Hepatol. 2017 Dec;67(6):1348-1350. doi: 10.1016/j.jhep.2017.06.035. Epub 2017 Aug 5.

DOI:10.1016/j.jhep.2017.06.035
PMID:28789880
Abstract
摘要

相似文献

1
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.在英国国家医疗服务体系（NHS）针对来自低收入和中等收入国家的罕见丙型肝炎病毒（HCV）亚型的早期获取项目中对直接抗病毒药物（DAA）疗法的反应。
J Hepatol. 2017 Dec;67(6):1348-1350. doi: 10.1016/j.jhep.2017.06.035. Epub 2017 Aug 5.
2
Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries".回复：“对英国国家医疗服务体系（NHS）英格兰早期准入计划中低收入国家罕见丙肝病毒亚型直接抗病毒药物（DAA）治疗的反应”
J Hepatol. 2017 Dec;67(6):1350-1352. doi: 10.1016/j.jhep.2017.07.019. Epub 2017 Aug 5.
3
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".回复：“回复：‘对英格兰国民保健制度针对低收入和中等收入国家罕见丙肝病毒亚型的早期获取项目中直接抗病毒药物治疗的回应’”
J Hepatol. 2018 Apr;68(4):864-866. doi: 10.1016/j.jhep.2017.11.044. Epub 2018 Jan 12.
4
Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England.在英国，与流行的丙型肝炎病毒亚型感染者相比，地方性丙型肝炎病毒亚型感染者接受直接抗病毒治疗的结果。
J Infect. 2025 Apr;90(4):106465. doi: 10.1016/j.jinf.2025.106465. Epub 2025 Mar 5.
5
Current Treatment Options in Patients with Hepatitis C Virus Genotype 6.丙型肝炎病毒基因6型患者的当前治疗选择
Gastroenterol Clin North Am. 2015 Dec;44(4):871-81. doi: 10.1016/j.gtc.2015.07.010. Epub 2015 Aug 8.
6
Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.丙型肝炎病毒的泛基因型治疗方案：高收入和低收入地区的优缺点
J Viral Hepat. 2017 Feb;24(2):92-101. doi: 10.1111/jvh.12635. Epub 2016 Nov 9.
7
Treatment of chronic HCV genotype 1 coinfection.慢性丙型肝炎病毒1型合并感染的治疗。
Curr HIV/AIDS Rep. 2015 Sep;12(3):326-35. doi: 10.1007/s11904-015-0278-4.
8
'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment.“不常见”的丙型肝炎病毒基因型亚型：起源、分布、对直接抗病毒药物的敏感性以及抗病毒治疗和再治疗情况
Gut. 2024 Aug 8;73(9):1570-1582. doi: 10.1136/gutjnl-2024-332177.
9
Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.丙型肝炎病毒1型中自然存在的与NS3耐药相关的变异体：它们对发展中国家的相关性。
Virus Res. 2016 Sep 2;223:140-6. doi: 10.1016/j.virusres.2016.07.008. Epub 2016 Jul 19.
10
Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.直接作用抗病毒疗法治疗丙型肝炎：南非开普敦大学/格罗特舒尔医院肝脏诊所的初步经验。
S Afr Med J. 2020 Jan 29;110(2):112-117. doi: 10.7196/SAMJ.2020.v110i2.14195.

引用本文的文献

1
Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.慢性丙型肝炎感染患者以及初次或再次使用泛基因型直接抗病毒药物治疗后病毒学失败患者中耐药相关替代位点的流行率：一项系统评价和荟萃分析
Clin Infect Dis. 2024 Dec 17;79(6):1437-1446. doi: 10.1093/cid/ciae431.
2
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.一组有欧洲直接抗病毒药物治疗经验患者中的罕见丙肝病毒亚型及再治疗结果
JHEP Rep. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072. eCollection 2024 Jul.
3
Identification of 2 Novel Subtypes of Hepatitis C Virus Genotype 8 and a Potential New Genotype Successfully Treated With Direct Acting Antivirals.
鉴定出丙型肝炎病毒基因8型的2种新型亚型及一种可用直接抗病毒药物成功治疗的潜在新基因型。
J Infect Dis. 2024 Dec 16;230(6):e1254-e1262. doi: 10.1093/infdis/jiae253.
4
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.伏西拉普瑞韦/维帕他韦/索磷布韦在直接抗病毒药物治疗失败患者中的真实世界有效性
JHEP Rep. 2024 Feb 7;6(3):100994. doi: 10.1016/j.jhepr.2023.100994. eCollection 2024 Mar.
5
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.在一项单臂机制性研究中，超短疗程、基于应答指导的索磷布韦和达卡他韦治疗丙型肝炎的疗效。
Elife. 2023 Jan 9;12:e81801. doi: 10.7554/eLife.81801.
6
Hepatitis C subtyping assay failure in UK patients born in sub-Saharan Africa: Implications for global treatment and elimination.在撒哈拉以南非洲出生的英国丙型肝炎患者的丙型肝炎亚型检测失败：对全球治疗和消除的影响。
J Med Virol. 2023 Jan;95(1):e28178. doi: 10.1002/jmv.28178. Epub 2022 Oct 8.
7
Effects of Achieving Sustained Virologic Response after Direct-Acting Antiviral Agents on Long-Term Liver Fibrosis in Diabetics vs. in Non-Diabetic Patients with Chronic Hepatitis C Infection.直接抗病毒药物治疗后实现持续病毒学应答对糖尿病与非糖尿病慢性丙型肝炎感染患者长期肝纤维化的影响。
Biomedicines. 2022 Aug 26;10(9):2093. doi: 10.3390/biomedicines10092093.
8
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure.病毒全基因组关联研究鉴定出与索非布韦治疗失败相关的新型丙型肝炎病毒变异。
Nat Commun. 2021 Oct 20;12(1):6105. doi: 10.1038/s41467-021-25649-6.
9
Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?丙型肝炎的管理和治疗：是否仍存在未解决的问题和特殊人群？
Viruses. 2021 Jun 1;13(6):1048. doi: 10.3390/v13061048.
10
Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.低、中收入国家的非流行型 HCV 基因型与现有直接作用抗病毒治疗方案耐药的风险。
J Hepatol. 2021 Aug;75(2):462-473. doi: 10.1016/j.jhep.2021.04.045. Epub 2021 May 8.